Working… Menu

Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03012321
Recruitment Status : Recruiting
First Posted : January 6, 2017
Last Update Posted : April 25, 2019
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Maha Hussain, Northwestern University

Brief Summary:
This is a biomarker preselected, randomized, open-label, multicenter, phase II study in men with metastatic castration resistant prostate cancer (mCRPC). Patients with tumors that have ATM, BRCA1 and/or BRCA2 mutations/deletions/loss of heterozygosity will be randomized in a 1:1:1 fashion to each arm. Patients with mutations in noncanonical DNA repair genes including FANCA, PALB2, RAD51, ERCC3, MRE11, NBN, MLH3, CDK12, CHEK2, HDAC2, ATR, PMS2, GEN1, MSH2, MSH6, BRIP1, or FAM175A defects will be assigned to Arm IV with single agent olaparib.

Condition or disease Intervention/treatment Phase
Prostate Cancer Metastatic Castration-Resistant Abnormal DNA Repair Metastatic Prostate Carcinoma Stage IV Prostate Cancer Drug: Olaparib Drug: Abiraterone Acetate Drug: Prednisone Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: BRCAAway: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
Study Start Date : January 2017
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : January 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Arm I: Abiraterone + Prednisone
Abiraterone 1000 mg orally once daily and prednisone 5 mg orally twice daily, days 1-28 in 28 day cycles.
Drug: Abiraterone Acetate
Drug: Prednisone
Active Comparator: Arm II: Olaparib
Olaparib 300 mg orally twice daily for days 1-28 in 28 day cycles.
Drug: Olaparib
Other Name: Lynparza

Active Comparator: Arm III: Abiraterone + Prednisone + Olaparib
Abiraterone 1000 mg orally once daily, prednisone 5 mg orally twice daily, olaparib 300 mg orally twice daily for days 1-28 in 28 day cycles.
Drug: Olaparib
Other Name: Lynparza

Drug: Abiraterone Acetate
Drug: Prednisone
Active Comparator: Olaparib
Olaparib 300 mg orally twice daily for days 1-28 in 28 day cycles.
Drug: Olaparib
Other Name: Lynparza

Primary Outcome Measures :
  1. Objective Progression Free Survival (PFS) [ Time Frame: Up to 2 years ]
    Evaluate the objective PFS of abiraterone/prednisone, olaparib or the combination abiraterone/prednisone + olaparib in mCRPC patients with canonical DNA repair defects in BRCA1, BRCA2, or ATM.

Secondary Outcome Measures :
  1. Measurable disease response rate by RECIST [ Time Frame: Up to 2 years ]
    Objective disease response (complete response [CR] + partial response [PR]) assessed using RECIST 1.1.

  2. PSA response rate [ Time Frame: Up to 2 years ]
    PSA response rate (CR + PR) will be measured.

  3. Rate of undetectable PSA [ Time Frame: Up to 2 years ]
    The rate of undetectable PSA (CR) will be measured.

  4. Poly[ADP-ribose] polymerase (PARP) inhibition [ Time Frame: Up to 2 years ]
    Evaluate if noncanonical DNA repair defects have clinical susceptibility to PARP inhibition alone.

  5. Incidence of Adverse Events [ Time Frame: Up to 2 years ]
    To evaluate the safety of the combination of abiraterone/prednisone + olaparib combination therapy. Adverse events will be assessed by the National Cancer Institute's CTCAE 4.0.

  6. The post progression response rate with cross over to olaparib or abiraterone [ Time Frame: Up to 2 years ]
    The response rate will be evaluated in patients who cross over to olaparib or abiraterone post progression on therapy with abiraterone or olaparib respectively by treatment arm.

  7. The post progression PFS with cross over to olaparib or abiraterone [ Time Frame: Up to 2 years ]
    The PFS will be evaluated in patients who cross over to olaparib or abiraterone post progression on therapy with abiraterone or olaparib respectively by treatment arm.

  8. Qualitative toxicities [ Time Frame: Up to 2 years ]
    Adverse Event summaries will be reported by treatment arm and organized by body system, frequency of occurrence, intensity (i.e., severity grade), and causality or attribution. Treatment exposure will be summarized for all patients, including dose administration, number of cycles, dose modifications or delays, and duration of therapy.

  9. Quantitative toxicities [ Time Frame: Up to 2 years ]
    Adverse Event summaries will be reported by treatment arm and organized by body system, frequency of occurrence, intensity (i.e., severity grade), and causality or attribution. Treatment exposure will be summarized for all patients, including dose administration, number of cycles, dose modifications or delays, and duration of therapy.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Ability to understand and the willingness to sign a written informed consent document that is approved by the local institutional review board and HIPAA authorization for the release of personal health information.
  • Histological or cytological proof of prostate adenocarcinoma (Note: small-cell carcinoma of the prostate is not permitted)
  • Documented progressive mCRPC based on at least one of the following criteria:

    1. PSA progression defined as 25% increase over baseline value with an increase in the absolute value of at least 2.0 ng/mL that is confirmed by another PSA level with a minimum of a 1 week interval and a minimum PSA of 2.0 ng/mL.
    2. Progression of bidimensionally measurable soft tissue or nodal metastasis assessed within one month prior to registration by a CT scan or MRI.
    3. Progression of bone disease (evaluable disease) (new bone lesion(s)) by bone scan.
  • Agree to undergo a biopsy of at least one metastatic site (fresh biopsy of primary prostate only allowed if there is clear local disease and no other measurable disease site or biopsiable bone lesion.) to determine DNA repair defects. (Please refer to the Laboratory Manual for specific procedures). However:

    1. Adequate archival metastatic or primary disease tumor tissue can be used if available in lieu of a new biopsy. These patients will only be eligible for protocol therapy if the biopsy has tumor that is positive for DNA repair defects.
    2. Patients with known DNA damage repair defects based on prior appropriately validated metastatic or prostate tissue analysis may be used in lieu of new biopsy/analysis based on central site evaluation of quality of the biopsy and analysis.
    3. Patients with known germline DNA repair defects are eligible without a biopsy. However it will be highly desirable that they undergo a metastatic (or fresh prostate biopsy if there is clear local disease and no other measurable disease site or biopsiable bone lesion) disease biopsy to better define the scope of the DNA repair defects in the current disease context.
  • ECOG status of 0-2 (Appendix A: Performance Status Criteria).
  • Adequate organ function as defined below obtained within 14 days of registration:

ANC > or = 1500/µl Hemoglobin ≥ 10.0 g/dL WBC > 3x10^9/L Platelet count 100,000/µl Creatinine ≥51 mL/min estimated using the Cockcroft-Gault equation Potassium ≥ 3.5 mmol/L (within institutional normal range) Bilirubin within normal institutional limits (or <2X the upper limit of normal (ULN) in those with Gilbert's disease) AST (SGOT) / ALT (SGPT) ≤ 1.5x institutional ULN unless liver metastases are present in which case it must be ≤ 5x ULN

  • The effects of abiraterone, olaparib or the combination of both on the developing human fetus at the recommended therapeutic dose are unknown. Men must agree to use adequate contraception prior to study entry, for the duration of study participation and for at least 3 months thereafter.
  • Patients must discontinue antiandrogen therapy (i.e., flutamide, bicalutamide, nilutamide) for at least 4 weeks prior to registration with no evidence of a falling PSA after washout.
  • Serum testosterone < 50 ng/dL. Patients must continue primary ADT with an LHRH analogue (agonist or antagonist) if they have not undergone orchiectomy.
  • Able to take oral medication without crushing, dissolving or chewing tablets.
  • Patients must have a life expectancy ≥ 6 months.
  • Patients may have received prior radiation therapy or surgery. However, at least 14 days must have elapsed since completion of radiation therapy or surgery and patient must have recovered from all side effects at the time of registration (e.g. back to baseline or grade 1) .
  • Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.

Exclusion Criteria:

  • Prior exposure to CYP17 (other than ketoconazole) or PARP inhibitors for prostate cancer. Patients with prior exposure to ketoconazole are eligible.
  • Prior chemotherapy for castration resistant disease. Chemotherapy given in the hormone-sensitive setting is permissible if stopped at least 4 weeks prior to registration.

Note: Patients can receive a stable dose of bisphosphonates for bone metastases, including zoledronic acid, or denosumab before and during the study as deemed appropriate by the treating physician.

  • Prior exposure to enzalutamide, ARN-509 or other investigational AR-directed therapy in the setting of mCRPC.
  • Patients with a currently active second malignancy excluding non-melanomatous skin cancer or superficial transitional cell carcinoma.

Note: Patients are not considered to have a "currently active" malignancy if they have completed all therapy and are now considered without evidence of disease for 1 year.

  • Patients receiving any other investigational agents. Any prior investigational agents must be stopped at least 14 days (2 week washout) prior to registration.
  • Patients who have received itraconazole, ketoconazole, or fluconazole within 3 weeks prior to registration or those who have not recovered (i.e., back to baseline or Grade 1) from AEs due to agents administered more than 3 weeks earlier.
  • Patients with a history of active seizures (or a single confirmed seizure event) in the last 2 years from the time of registration.
  • Patients with a history of pituitary or adrenal dysfunction or active or symptomatic viral hepatitis or chronic liver disease are not eligible.
  • Patients with active brain metastases. A scan to confirm the absence of brain metastases is not required for asymptomatic patients.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib or abiraterone.
  • Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, unstable spinal cord compression (untreated or unstable within at least 28 days prior to registration), superior vena cava syndrome, and extensive bilateral lung disease on HRCT scan or any psychiatric disorder that prohibits obtaining informed consent.
  • Patients with prolonged pre-existing hematological toxicities including known indicators of bone marrow failure or abnormality.
  • Patients with myelodysplastic syndrome / acute myeloid leukemia.
  • Patients may continue on a daily Multi-Vitamin, calcium and Vitamin D, but all other herbal, alternative and food supplements (i.e. PC-Spes, Saw Palmetto, St John's Wort, etc.) must be discontinued before starting protocol treatment. Hormonal-acting agents such as DES are forbidden during the trial and must be stopped prior to starting protocol treatment. No washout period will be required. Patients on megesterol acetate for hot flashes are allowed to continue therapy.
  • Patients must stop taking ritonavir, idinavir, saquinavir, telithromycin, clarithromycin and nelfinavir 1 week prior to registration. Note: topical ketoconazole is permitted.
  • Patients must stop taking phenytoin, rifampicin, rifapentine, rifabutin, carbamazepine, nevirapine, modafinil and St John's Wort (Hypericum perforatum) 3 weeks prior to registration.

Patients must stop taking phenobarbitone 5 weeks prior to registration.

Patients must stop taking all strong CYP3A4 inhibitors, including clarithromycin, telithromycin, nefazodone, itraconazole, ketoconazole, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, and tipranavir, prior to registration.

  • Patients must not be planning to receive any concurrent cytotoxic chemotherapy, surgery or radiation therapy during protocol treatment.
  • Use of any prohibited concomitant medications within 7 days of registration.
  • Patients who are HIV-positive on combination antiretroviral therapy because of the potential for pharmacokinetic interactions with olaparib. In addition these patients are at increased risk of lethal infections when treated with marrow suppressive therapy.
  • Patients with known active Hepatitis B or Hepatitis C.
  • Patients with baseline moderate to severe hepatic impairment (Child-Pugh Class B and C).
  • Persistent toxicities (≥CTCAE Grade 2), with the exception of alopecia, caused by previous cancer therapy.
  • Resting ECG with QTc > 470msec on 2 or more time points within a 24 hour period or of long QT syndrome.
  • Patients with significant cardiac history including:

    • Severe or unstable angina pectoris
    • Uncontrolled hypertension (defined as systolic BP ≥ 160 mmHg or diastolic BP ≥ 95 mmHg). Note - Patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment
    • Atrial fibrillation or other cardiac arrhythmia requiring therapy.
    • Heart disease as evidenced by myocardial infarction, or aterial thrombotic events in the past 6 months
    • Class II-IV heart failure (as defined by New York Heart Association) or a cardiac ejection fraction measurement of less than 50% at baseline
  • Blood transfusion within 30 days of consent.
  • Previous allogeneic bone marrow transplant.
  • Major surgery within 14 days of registration and patients must have recovered from any effects of any major surgery.
  • Patients with any condition likely to interfere with absorption of the study medication.
  • No other condition which, in the opinion of the Investigator, would preclude participation in this trial.
  • Patients who have noncanonical DNA repair defects and extensive visceral disease or symptomatic bone disease requiring urgent tumor response.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03012321

Layout table for location contacts
Contact: Study Coordinator (312)695-1301

Layout table for location information
United States, California
City of Hope National Medical Center Active, not recruiting
Duarte, California, United States, 91010
University of California Los Angeles Recruiting
Los Angeles, California, United States, 90073
Contact: Matthew Rettig, MD    310-268-3622      
Principal Investigator: Matthew Rettig, MD         
United States, Florida
H. Lee Moffitt Cancer Center and Research Institute Recruiting
Tampa, Florida, United States, 33612
Contact: Jingsong Zhang, MD    813-745-4673      
Principal Investigator: Jingsong Zhang, MD         
United States, Illinois
Northwestern Medicine Recruiting
Chicago, Illinois, United States, 60611
Contact: Maha Hussain, MD, FACP, FASCO    312-695-6180      
Principal Investigator: Maha Hussain, MD, FACP, FASCO         
Sub-Investigator: Alicia K. Morgans, MD, MPH         
Rush University Cancer Center Recruiting
Chicago, Illinois, United States, 60612
Contact: Nicklas Pfanzelter, MD    312-942-5904      
Principal Investigator: Nicklas Pfanzelter, MD         
University of Chicago Recruiting
Chicago, Illinois, United States, 60637
Contact: Russell Szmulewitz, MD    773-702-7609      
Principal Investigator: Russell Szmulewitz, MD         
Kellogg Cancer Center - NorthShore University Recruiting
Evanston, Illinois, United States, 60201
Contact: Daniel Shevrin, MD    847-570-2515      
Principal Investigator: Daniel Shevrin, MD         
United States, Indiana
Indiana University/ Melvin and Bren Simon Cancer Center Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Roberto Pili, MD    317-948-8310      
Principal Investigator: Roberto Pili, MD         
United States, Maryland
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Recruiting
Baltimore, Maryland, United States, 21231
Contact: Emmanuel Antonarakis, MD    410-502-7528      
Principal Investigator: Emmanuel Antonarakis, MD         
United States, Michigan
University of Michigan Health System Recruiting
Ann Arbor, Michigan, United States, 48109-5946
Contact: Todd Morgan, M.D.    734-647-8903      
Sub-Investigator: Todd Morgan, M.D.         
Sub-Investigator: Zachery Reichert, M.D., Ph.D.         
Sub-Investigator: Arul Chinnaiyan, M.D., Ph.D.         
Sub-Investigator: Scott Tomlins, M.D., Ph.D.         
Karmanos Cancer Center Active, not recruiting
Detroit, Michigan, United States, 48201
United States, Minnesota
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Manish Kohli, M.D.    507-538-3270      
Principal Investigator: Manish Kohli, M.D.         
United States, Missouri
Washington University School of Medicine Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Joel Picus, MD    314-747-9281      
Principal Investigator: Joel Picus, MD         
United States, New Jersey
Rutgers Cancer Institute of New Jersey Active, not recruiting
New Brunswick, New Jersey, United States, 08903
United States, New York
Weill Cornell Medical College Recruiting
New York, New York, United States, 10065
Contact: Himisha Beltran, MD    646-962-2072      
Principal Investigator: Himisha Beltran, MD         
United States, North Carolina
University of North Carolina at Chapel Hill Recruiting
Chapel Hill, North Carolina, United States, 27514
Contact: Young Whang, MD    919-966-4996      
Principal Investigator: Young Whang, MD         
United States, Utah
Huntsman Cancer Institute - University of Utah Recruiting
Salt Lake City, Utah, United States, 84112
Contact: Neeraj Agarwal, MD    801-585-0100      
Principal Investigator: Neeraj Agarwal, MD         
United States, Virginia
University of Virginia Recruiting
Charlottesville, Virginia, United States, 22903
Contact: Robert Dreicer, MD    434-924-9333      
Principal Investigator: Robert Dreicer, MD         
Sponsors and Collaborators
Northwestern University
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Maha Hussain, MD, FACP, FASCO Northwestern University

Layout table for additonal information
Responsible Party: Maha Hussain, Maha Hussain, MD, FACP, FASCO, Northwestern University Identifier: NCT03012321     History of Changes
Other Study ID Numbers: NU_16U05
STU00203960 ( Other Identifier: Northwestern IRB )
NCI-2016-01834 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
PCCTC #: c16-168 ( Other Identifier: PCCTC )
First Posted: January 6, 2017    Key Record Dates
Last Update Posted: April 25, 2019
Last Verified: April 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Abiraterone Acetate
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Poly(ADP-ribose) Polymerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Hormone Antagonists
Cytochrome P-450 Enzyme Inhibitors